Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
作者： Anja Von Heydebreck , Christopher Stroh
DOI:
关键词:
摘要: The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in treatment EGFR expressing cancer. is further related prediction sensitivity or resistance a patient suffering from cancer said with specific anti- antibody. preferably identification respective that allow better clinical outcome patients KRAS wild-type tumors. In this context, especially anti-EFGR antibody c225/cetuximab (Erbitux®) its use colorectal Cancer (CRC).
lens.org 参考文章(44)
Shirin K. Ford, Edwin A. Clark, Xin Huang, Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators ,(2006)
Sabine Tejpar, Wendy De Roock, Hubert Piessevaux, Jef De Schutter, Marc Peeters, Ilhan Celik, Bart Biesemans, Yves Humblet, Eric Van Cutsem, High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease Molecular Cancer Therapeutics. ,vol. 6, ,(2007)
J. B. Baker, D. Dutta, D. Watson, T. Maddala, S. Shak, E. K. Rowinsky, L. Xu, E. Clark, D. J. Mauro, S. Khambata-Ford, Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer Journal of Clinical Oncology. ,vol. 26, pp. 3512- 3512 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.3512
Tara Maddala, David J. Mauro, Shirin K. Ford, Drew Watson, Steven Shak, Joffre B. Baker, Predictors of patient response to treatment with EGF receptor inhibitors ,(2009)
Aurélien de Reyniès, Valérie Boige, Gérard Milano, Jean Faivre, Pierre Laurent-Puig, KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. Journal of Clinical Oncology. ,vol. 26, pp. 2228- 2230 ,(2008) , 10.1200/JCO.2007.15.9186
Manfred Kunz, Genomic signatures for individualized treatment of malignant tumors. Current Drug Discovery Technologies. ,vol. 5, pp. 9- 14 ,(2008) , 10.2174/157016308783769423
Zhijin Wu, Rafael A Irizarry, Robert Gentleman, Francisco Martinez-Murillo, Forrest Spencer, A Model-Based Background Adjustment for Oligonucleotide Expression Arrays Journal of the American Statistical Association. ,vol. 99, pp. 909- 917 ,(2004) , 10.1198/016214504000000683
Steven M. Pollard, Richard Wallbank, Simon Tomlinson, Lars Grotewold, Austin Smith, Fibroblast growth factor induces a neural stem cell phenotype in foetal forebrain progenitors and during embryonic stem cell differentiation Molecular and Cellular Neuroscience. ,vol. 38, pp. 393- 403 ,(2008) , 10.1016/J.MCN.2008.03.012
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Bruno Vincenzi, Daniele Santini, Antonio Russo, Michele Gavasci, Fabrizio Battistoni, Giordano Dicuonzo, Laura Rocci, Valerio Maria Rosaria, Nicola Gebbia, Giuseppe Tonini, Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan Pharmacogenomics. ,vol. 8, pp. 319- 327 ,(2007) , 10.2217/14622416.8.4.319